NorthWest Biotherapeutics Inc (NWBO)

[Schnauzer1]

Senti,

The issue of discounting the spread is for OS, which I understand to be a general requirement after AA. So if the L therapy is effective then why would NWBO design the PIII to reduce the evidence of effectiveness by giving control that medicine? This is very disconcerting to me. Someone was stating that the effectiveness of the vaccine is reduced as the number of cancer cells increases, as a reason why OS would not matter as an endpoint. Somehow thinking that this point justified the cross. My statement was a mere retort to that idea, that is if its so ineffective as patients hit the PFS point then what is the reason to put control on it anyway.

Thanks for the link.

Thanks for responding.